Phase 2 N=12 Anti-malaria MAb in Kenyan Children
Plasmodium Falciparum Infection · Malaria
Primary: Number of Participants With Local Adverse Events (AEs) — 0; 1; 1; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=100 Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial
Postpartum Hemorrhage · Uterine Atony
Primary: Uterine Tone Score — 4.7; 4.4 score on a scale
N/A N=112 Million Veteran Program Return of Actionable Results
Cardiovascular Disease
Primary: LDL-C Change — -8.0; 2.4 mg/dL
Phase 2 N=103 A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Change From Baseline in Disease Activity Index Score 28 Using C-reactive Protein (DAS28-CRP) at Week 12 — -1.86; -1.92 Score on a Scale — p==0.822
N/A N=439 Preventing Alcohol Exposed Pregnancy Among Urban Native Young Women: Mobile CHOICES
Alcohol Exposed Pregnancy
Primary: Alcohol Use — 86; 82; 131; 137 Participants
Phase 3 N=59 Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Participants With Adverse Events (AEs) — 55; 15 Participants
N/A N=113 Sub-Threshold Exercise Treatment for Adolescents With Sports Related Concussion
Brain Injury · Concussion
Primary: Time (in Days) to Recovery — 13; 17 Days
Phase 3 N=109 Effectiveness of Dapagliflozin for Weight Loss
PreDiabetes · Obesity, Morbid · Diabetes Mellitus, Type 2
Primary: Change in Weight — 121.5; 125.9; 118; 123.7 kg — p=<0.05
Phase 1 N=12 Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function
Renal Impairment · Tuberculosis
Primary: Fold Change in Pretomanid AUC(0-last) in Participants With Renal Impairment as Compared to Matched Healthy Controls — 77130; 63600; 62660 ng*h/mL
N/A N=21 Motivating Occupational Virtual Experiences In Therapy for Kids
Virtual Reality · Occupational Therapy
Primary: Pre Jebsen Taylor Hand Function Test (JTHFT) — 433.9; 294.7 seconds
Phase 2 N=22 POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis
Atopic Dermatitis
Primary: Proportion of Patients Achieving at Least 75% Reduction in Eczema Area and Severity Index [EASI] at Week 26 — 94.1 percentage of patients achieved EASI75
Phase 2 N=263 Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
Alzheimer's Disease (AD)
Primary: Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 14) Score at Week 12 — -1.26; -1.28; -1.68; -1.01 score on a scale — p=0.9819
Phase 2 N=188 Early Communication Intervention for Toddlers With Hearing Loss
Hearing Loss, Bilateral
Primary: Use of Communication Support Strategies - Parent — .60; .02 units on a scale
Phase 2 N=24 A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
Biochemically Recurrent Prostate Cancer
Primary: Percent Change in Serum Testosterone — 53.46 percentage (%)
Phase 2 N=112 A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia
Early Course Schizophrenia Spectrum Disorder
Primary: Neural Activity Across Brain Regions During a Spatial Working Memory (sWM) Task- Condition 2 — -0.076; -0.090; -0.072; -0.136 percentage signal change